ATNM Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Actinium Pharmaceuticals Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerATNM

Market Cap38.1M

Cash RunwayRunway > 12 months

Next Catalyst2026-12-31

Public Research Snapshot

Actinium Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Video Gallery (Phase 3) using Cell Therapy.

Pipeline

Asset	Indication	Modality	Stage	Public Note
ATNM-400	n/a	Cell Therapy	n/a	Public pipeline row
Video Gallery	n/a	n/a	Phase 3	Public pipeline row
Actinium-J591	Prostate Cancer Metastatic	n/a	Phase 1	Public pipeline row
[Ac 225]RTX-2358	Advanced Soft Tissue Sarcoma	n/a	Phase 1	Public pipeline row
Actinium Ac 225 DOTATATE RYZ101	Recurrent Meningioma	n/a	Phase 1 \| Phase 2	Public pipeline row
Lintuzumab-Ac225	Acute Myeloid Leukemia \| Relapsed Adult AML	n/a	Phase 1 \| Phase 2	Public pipeline row
RYZ101	Metastatic Breast Cancer \| HER2-negative Breast Cancer \| ER+ Breast Cancer \| Advanced Breast Cancer	n/a	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2026-12-31	Actinium Ac 225 DOTATATE RYZ101	Low
Clinical Trial Completion	2028-01	[Ac 225]RTX-2358	Low
Clinical Trial Completion	2028-10	RYZ101	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03932318	Phase 1 \| Phase 2	WITHDRAWN	n/a	2023-12
NCT05567770	Phase 1	WITHDRAWN	n/a	2025-01
NCT07150806	Phase 1 \| Phase 2	RECRUITING	30	2026-12-31
NCT07156565	Phase 1	RECRUITING	30	2028-01
NCT06590857	Phase 1 \| Phase 2	ACTIVE_NOT_RECRUITING	16	2028-10

Scientific Context

conditions | Prostate Cancer Metastatic
conditions | Advanced Soft Tissue Sarcoma
conditions | Recurrent Meningioma
conditions | Acute Myeloid Leukemia | Relapsed Adult AML
conditions | Metastatic Breast Cancer | HER2-negative Breast Cancer | ER+ Breast Cancer | Advanced Breast Cancer

Want the full ATNM research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.